CO5150149A1 - Composiciones farmaceuticas derivadas de quinolina - Google Patents
Composiciones farmaceuticas derivadas de quinolinaInfo
- Publication number
- CO5150149A1 CO5150149A1 CO99072805A CO99072805A CO5150149A1 CO 5150149 A1 CO5150149 A1 CO 5150149A1 CO 99072805 A CO99072805 A CO 99072805A CO 99072805 A CO99072805 A CO 99072805A CO 5150149 A1 CO5150149 A1 CO 5150149A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- optionally substituted
- aryl
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto, o un solvato o una sal de éste, de fórmula (I).<EMI FILE="99072805_1" ID="1" IMF=JPEG >en la que Ar es un grupo arilo o cicloalcadienilo C5-7 opcionalmente sustituido, o un grupo cicloalquilo C5-7 opcionalmente sustituido, o un grupo heterocíclico aromático de un único anillo o de anillos condensados, opcionalmente sustituido; R es hidrógeno, alquilo C1-6 lineal o ramificado, cicloalquilo C3-7, cicloalquil-C3-7-alquilo; R1 representa hidrógeno o hasta tres sustituyentes opcionales seleccionados entre la lista que consta: alquilo C1-6, alquenilo C1-6, arilo, alcoxi C1-6, hidroxi, halógeno, nitro, ciano, carboxi, carboxamido, sulfonamido, alcoxi C1-6-carbonilo, trifluorometilo, aciloxi, amino o mono- y di-alquil C1-6-amino; R2 representa un resto -(CH2)n-NY1Y2 en la que n es un número entero en el margen de 1 a 9, Y1 e Y2 se seleccionan independientemente entre alquilo C1-6; alquilo C1-6 sustituido con hidroxi, alcoxi, alquil C1-6-amino o bis (alquil C1-6)-amino; cicloalquilo C3-6; aza-cicloalquilo C4-6; alquenilo C1-6; arilo o aril-alquilo C1-6, o Y1 e Y2 conjuntamente con el átomo de nitrógeno al que están unidos, representan un grupo heterocíclico de anillo único o de anillos condensados enlazados en N, opcionalmente sustituido; R3 es alquilo C1-6 lineal o ramificado, cicloalquilo C3-7, cicloalquil-alquilo C4-7, arilo opcionalmente sustituido o un grupo heterocíclico aromático de un único anillo o de anillos condensados, opcionalmente sustituido; y R4 representa hidrógeno o alquilo C1-6, R5 representa hidrógeno o halógeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9825553.2A GB9825553D0 (en) | 1998-11-20 | 1998-11-20 | Novel Compounds |
GBGB9825552.4A GB9825552D0 (en) | 1998-11-20 | 1998-11-20 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5150149A1 true CO5150149A1 (es) | 2002-04-29 |
Family
ID=26314705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99072805A CO5150149A1 (es) | 1998-11-20 | 1999-11-19 | Composiciones farmaceuticas derivadas de quinolina |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1131295A1 (es) |
JP (1) | JP2002530377A (es) |
KR (1) | KR20010075726A (es) |
CN (1) | CN1406225A (es) |
AR (2) | AR021355A1 (es) |
AU (1) | AU768708B2 (es) |
BR (1) | BR9915475A (es) |
CA (1) | CA2351865A1 (es) |
CO (1) | CO5150149A1 (es) |
HK (1) | HK1041257A1 (es) |
HU (1) | HUP0104959A3 (es) |
IL (1) | IL143137A0 (es) |
MX (1) | MXPA01005095A (es) |
NO (1) | NO20012473L (es) |
NZ (1) | NZ511777A (es) |
PL (1) | PL347721A1 (es) |
TR (1) | TR200101412T2 (es) |
WO (1) | WO2000031037A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
GB0027701D0 (en) * | 2000-11-13 | 2000-12-27 | Smithkline Beecham Spa | Novel compounds |
JP2004517062A (ja) * | 2000-11-13 | 2004-06-10 | グラクソスミスクライン・ソシエタ・ペル・アチオニ | Nk−3およびnk−2アンタゴニストとしてのキノリン誘導体 |
EP1351953A1 (en) * | 2000-11-28 | 2003-10-15 | GlaxoSmithKline S.p.A. | Quinoline derivatives as nk-3 antagonists |
AU2002221923A1 (en) * | 2000-11-28 | 2002-06-11 | Glaxosmithkline S.P.A. | Novel compounds |
GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
WO2002083673A1 (en) | 2001-04-10 | 2002-10-24 | Ortho-Mcneil Pharmaceutical, Inc. | 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
ATE313539T1 (de) * | 2001-04-11 | 2006-01-15 | Glaxosmithkline Spa | Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten |
GB0109122D0 (en) * | 2001-04-11 | 2001-05-30 | Smithkline Beecham Spa | Novel compounds |
MY134211A (en) * | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
AU2003244080A1 (en) * | 2002-06-26 | 2004-01-19 | Kyowa Hakko Kogyo Co., Ltd. | Phosphodiesterase inhibitor |
AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
GB0303086D0 (en) | 2003-02-11 | 2003-03-19 | Merck Sharp & Dohme | New compounds |
WO2005000247A2 (en) * | 2003-06-25 | 2005-01-06 | Smithkline Beecham Corporation | 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
GB0419192D0 (en) | 2004-08-27 | 2004-09-29 | Merck Sharp & Dohme | Therapeutic agents |
GB0425076D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0509405D0 (en) * | 2005-05-10 | 2005-06-15 | Merck Sharp & Dohme | Therapeutic compounds |
WO2006130080A2 (en) * | 2005-06-03 | 2006-12-07 | Astrazeneca Ab | Quinoline derivatives as nk3 anatgonists |
GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
AR057130A1 (es) | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
WO2007039123A2 (en) * | 2005-09-22 | 2007-04-12 | Smithkline Beecham Corporation | Combination therapy comprising an nk-3 antagonist and an antipsychotic agent |
TW200804288A (en) * | 2005-12-12 | 2008-01-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
US20090325992A1 (en) * | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
CA2670858C (en) | 2006-11-28 | 2015-01-13 | Janssen Pharmaceutica N.V. | Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
US20080221161A1 (en) * | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
EP2150552B1 (en) | 2007-04-09 | 2013-01-02 | Janssen Pharmaceutica NV | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression |
EP2549872B1 (en) * | 2010-03-23 | 2015-11-25 | GlaxoSmithKline LLC | Trpv4 antagonists |
EP2986293A1 (en) | 2013-04-19 | 2016-02-24 | Astrazeneca AB | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2227769T3 (es) * | 1994-05-27 | 2005-04-01 | Glaxosmithkline S.P.A. | Derivados de quinolina como antagonistas del receptor nk3 de taquiquinina. |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
ATE244711T1 (de) * | 1997-05-23 | 2003-07-15 | Glaxosmithkline Spa | Chinolin-4-carboxamidderivate als nk-2 und nk-3 rezeptor antagonisten |
-
1999
- 1999-11-19 NZ NZ511777A patent/NZ511777A/en unknown
- 1999-11-19 PL PL99347721A patent/PL347721A1/xx unknown
- 1999-11-19 TR TR2001/01412T patent/TR200101412T2/xx unknown
- 1999-11-19 HU HU0104959A patent/HUP0104959A3/hu unknown
- 1999-11-19 AU AU17770/00A patent/AU768708B2/en not_active Ceased
- 1999-11-19 WO PCT/EP1999/009115 patent/WO2000031037A1/en not_active Application Discontinuation
- 1999-11-19 JP JP2000583865A patent/JP2002530377A/ja active Pending
- 1999-11-19 BR BR9915475-7A patent/BR9915475A/pt not_active IP Right Cessation
- 1999-11-19 EP EP99961001A patent/EP1131295A1/en not_active Withdrawn
- 1999-11-19 IL IL14313799A patent/IL143137A0/xx unknown
- 1999-11-19 AR ARP990105927A patent/AR021355A1/es not_active Application Discontinuation
- 1999-11-19 CA CA002351865A patent/CA2351865A1/en not_active Abandoned
- 1999-11-19 KR KR1020017006343A patent/KR20010075726A/ko not_active Application Discontinuation
- 1999-11-19 CO CO99072805A patent/CO5150149A1/es unknown
- 1999-11-19 MX MXPA01005095A patent/MXPA01005095A/es unknown
- 1999-11-19 CN CN99815753A patent/CN1406225A/zh active Pending
- 1999-11-19 AR ARP990105926A patent/AR021354A1/es unknown
-
2001
- 2001-05-18 NO NO20012473A patent/NO20012473L/no not_active Application Discontinuation
-
2002
- 2002-02-08 HK HK02101024.6A patent/HK1041257A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000031037A1 (en) | 2000-06-02 |
EP1131295A1 (en) | 2001-09-12 |
AU768708B2 (en) | 2004-01-08 |
JP2002530377A (ja) | 2002-09-17 |
AR021354A1 (es) | 2002-07-17 |
PL347721A1 (en) | 2002-04-22 |
NZ511777A (en) | 2003-12-19 |
CA2351865A1 (en) | 2000-06-02 |
MXPA01005095A (es) | 2002-04-24 |
AU1777000A (en) | 2000-06-13 |
NO20012473D0 (no) | 2001-05-18 |
HUP0104959A3 (en) | 2003-01-28 |
HK1041257A1 (zh) | 2002-07-05 |
KR20010075726A (ko) | 2001-08-09 |
TR200101412T2 (tr) | 2001-10-22 |
IL143137A0 (en) | 2002-04-21 |
AR021355A1 (es) | 2002-07-17 |
NO20012473L (no) | 2001-07-18 |
HUP0104959A2 (hu) | 2002-04-29 |
BR9915475A (pt) | 2001-12-18 |
CN1406225A (zh) | 2003-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5150149A1 (es) | Composiciones farmaceuticas derivadas de quinolina | |
AR038383A1 (es) | Compuesto inhibidor de la hepatitis c | |
EA200000334A1 (ru) | Производные карбоксамидотиазолов, их получение, содержащие их фармацевтические композиции | |
HRP20050390A2 (en) | Substituted benzoxazinones and uses thereof | |
CO4950515A1 (es) | Nuevos derivados de la quinolina para uso medicinal | |
AR004706A1 (es) | Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo. | |
MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
NL1018251A1 (nl) | Organometallic monoacylalkylphosphines. | |
CO5280059A1 (es) | Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones | |
AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
PA8654501A1 (es) | Derivados de quinazolina inhibidores de quinasas dirigidos a multiples blancos | |
EA200400763A1 (ru) | Замещенные фенилпроизводные соединения | |
CY1109886T1 (el) | Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες | |
EA200401540A1 (ru) | Спироиндолинпиперидиновые производные | |
CY1114932T1 (el) | Αντιπαρασιτικοι παραγοντες | |
EA200800372A1 (ru) | Соединения и их соли, специфичные к ppar рецепторам и egf рецепторам, и их применение в области медицины | |
HUP0300909A2 (hu) | NHE-3 inhibitor hatású 2-guanidino-4-aril-kinazolin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
EA200201071A1 (ru) | Циклопентилзамещенные производные глутарамида в качестве ингибиторов нейтральной эндопептидазы | |
EA200300927A1 (ru) | Новый способ промышленного синтеза тетрасложных эфиров 5-[бис(карбоксиметил)амино]-3-карбоксиметил-4-циано-2-тиофенкарбоновой кислоты и применение для синтеза бивалентных солей ранелиновой кислоты и их гидратов | |
GB9825554D0 (en) | Novel Compounds | |
CY1111606T1 (el) | Διαδικασια διαχωρισμου για to (r)-(-)-2-yδροξy-2- (2-χλωροφαινυλ) οξικο οξυ | |
DK1202954T3 (da) | Nye aminobenzophenoner | |
CO6311082A2 (es) | Derivados de sulfonil-quinolina, procesos para su preparación y composiciones farmacéuticas que los contienen | |
EA200200807A1 (ru) | Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece | |
CO5150201A1 (es) | Derivados de piperidina |